Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

MISSISSAUGA, ON, Feb. 5 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a biotechnology Company focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that Chris Waddick, President and CEO, will present a Company Overview at BIO CEO & Investor Conference at the Waldorf Astoria, New York City, at 11:00 a.m. (ET) on Tuesday, February 12, 2008. The presentation will be webcast live at http://www.vasogen.com and a replay will also be accessible at http://www.vasogen.com.

Dr. Eldon Smith, Vasogen's Senior Vice President, Scientific Affairs and Chief Medical Officer, has also been selected as a member of the expert panel of the Non-Cancer Immunotherapy session. This workshop will take place on Wednesday, February 13, 2008, at 9:30 a.m. (ET). This event will not be webcast.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is al
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24, 2013 Die Übersetzungen wurden ... Bei der englischen Version handelt es ... % der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren ... GINA [*] -Definition [1] als kontrolliert gelten können ... generell einer von vier Denkweisen zugeordnet werden können, die ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Calif., May 19, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $5 million milestone payment from GlaxoSmithKline (GSK) ... study for ISIS-TTRRx.  ISIS-TTRRx is designed to treat transthyretin ... slow degeneration of peripheral nerve and/or heart tissues . ...
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... NEW YORK, May 18, 2011 Oppenheimer & Co. Inc., ... Matthias Spaenle, MD will join the firm as Managing Director ... he will help to drive its life science business. He ... Healthcare Investment Banking.   Since 2003, Matthias had ...
Cached Biology Technology:Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 2Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 4TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2
(Date:5/23/2013)... natural history museums of the world are billions of ... to flowers, mushrooms and grasses, all stacked, stored and ... and diverse collections could be critical to understanding how ... a growing human footprint if only the information ... to life with the help of a team from ...
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... new, streamlined approach to genetic engineering drastically reduces ... genes into bacteria, the workhorses of biotechnology, scientists ... Synthetic Biology , the method paves the way ... drug development, environmental cleanup and other activities. , ... integrating, a piece of the genetic material DNA ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... one of the great advances of the 19th and 20th ... too wet to farm. In fact, installation of new tile ... yields. But a recent study shows that the most heavily ... source of nitrate to the Gulf of Mexico, leading to ...
... WASHINGTON, Sept. 27 Several thousand federal, state and ... gather at Northern Virginia,s Stafford Regional Airport next May ... technology for countering terrorist threats to personnel, equipment and ... domestic settings within the U.S. and abroad. ...
... findings from an upcoming new report by the International ... poor state of post-fracture care in the Russian Federation ... were announced today at a press conference in St. ... Central Asian Osteoporosis Patient Societies. Osteoporosis, a disease ...
Cached Biology News:Tile drainage directly related to nitrate loss 2Tile drainage directly related to nitrate loss 3Industry to Demonstrate Off-the-Shelf Integrated Force Protection and Counter-Terrorism Solutions at Northern Virginia Site 2Industry to Demonstrate Off-the-Shelf Integrated Force Protection and Counter-Terrorism Solutions at Northern Virginia Site 3High death and disability rates due to fractures in Russia, Central Asia and Eastern Europe 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: